Re: Genentech receives FDA Refuse to File Letter for T-DM1
This is terrible and the fact that they say "the T-DM1 trials did not meet the standard for accelerated approval because all available treatment choices approved for metastatic breast cancer, regardless of HER2 status, had not been exhausted in the study population."
what has non-HER2 bc got to do with HER2 positive cancer????!!!
It's outrageous and a letter writing campaign to representatives in Congress is in order. I'm sure Genetech will be helpful in suggesting the best course of action.
sarah
__________________
|